Health-related quality-of-life assessment in patients with cutaneous T-cell lymphoma

被引:63
作者
Demierre, MF
Tien, A
Miller, D
机构
[1] Boston Univ, Med Ctr, Sch Med, Skin Oncol Program,Dept Dermatol, Boston, MA 02118 USA
[2] Boston Univ, Med Ctr, Sch Med, Dept Med, Boston, MA 02118 USA
[3] Boston Univ, Sch Publ Hlth, Boston, MA 02118 USA
关键词
D O I
10.1001/archderm.141.3.325
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Objective: To measure and evaluate the health-related quality of life (HRQOL) in patients with cutaneous T-cell lymphoma (CTCL), a visible cutaneous malignancy that may have a profound effect on patients' lives. Design: Monocenter, cross-sectional study Setting: The Skin Oncology Program, Department of Dermatology, and the Photopheresis Unit of Boston Medical Center. Patients: A total of 22 adult patients with confirmed CTCL. Main Outcome Measures: (1) Evaluation of general oncologic and skin disease-specific HRQOL using, respectively, the Functional Assessment of Cancer Therapy-General (FACT-G) and Skindex-29 profiles; (2) assessment of HRQOL association with disease stage (early stage, IA-IIA; late stage, IIB-IVB). Results: Patients with more advanced CTCL stages reported more effects on general health (FACT-G), particularly in the physical, emotional, and functional domains (P<.05). Patients with early-stage CTCL reported better skin-specific HRQOL overall (Skindex-29; P=.002) and for each specific domain than did patients with late-stage disease. The Skindex-29 scales had high internal consistency, and the confirmatory factor structure was similar to that of previous studies. Conclusions: The HRQOL of patients with CTCL can be evaluated using the Skindex-29 and FACT-G instruments. Patients with more advanced stages of CTCL had lower HRQOL scores.
引用
收藏
页码:325 / 330
页数:6
相关论文
共 39 条
[1]  
[Anonymous], 1996, J Clin Oncol, V14, P671
[2]  
Beitz J, 1996, J Natl Cancer Inst Monogr, P7
[3]   Extracorporeal photochemotherapy alone or with adjuvant therapy in the treatment of cutaneous T-cell lymphoma: A 9-year retrospective study at a single institution [J].
Bisaccia, E ;
Gonzalez, J ;
Palangio, M ;
Schwartz, J ;
Klainer, AS .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2000, 43 (02) :263-271
[4]   Multilingual translation of the functional assessment of cancer therapy (FACT) quality of life measurement system [J].
Bonomi, AE ;
Cella, DF ;
Hahn, EA ;
Bjordal, K ;
SpernerUnterweger, B ;
Gangeri, L ;
Bergman, B ;
WillemsGroot, J ;
Hanquet, P ;
Zittoun, R .
QUALITY OF LIFE RESEARCH, 1996, 5 (03) :309-320
[5]   Reliability and validity of the functional assessment of cancer therapy-breast quality-of-life instrument [J].
Brady, MJ ;
Cella, DF ;
Mo, F ;
Bonomi, AE ;
Tulsky, DS ;
Lloyd, SR ;
Deasy, S ;
Cobleigh, M ;
Shiomoto, G .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (03) :974-986
[6]   VALIDATING THE SF-36 HEALTH SURVEY QUESTIONNAIRE - NEW OUTCOME MEASURE FOR PRIMARY CARE [J].
BRAZIER, JE ;
HARPER, R ;
JONES, NMB ;
OCATHAIN, A ;
THOMAS, KJ ;
USHERWOOD, T ;
WESTLAKE, L .
BMJ-BRITISH MEDICAL JOURNAL, 1992, 305 (6846) :160-164
[7]   Advances in quality of life measurements in oncology patients [J].
Cella, D ;
Chang, CH ;
Lai, JS ;
Webster, K .
SEMINARS IN ONCOLOGY, 2002, 29 (03) :60-68
[8]   THE FUNCTIONAL ASSESSMENT OF CANCER-THERAPY SCALE - DEVELOPMENT AND VALIDATION OF THE GENERAL MEASURE [J].
CELLA, DF ;
TULSKY, DS ;
GRAY, G ;
SARAFIAN, B ;
LINN, E ;
BONOMI, A ;
SILBERMAN, M ;
YELLEN, SB ;
WINICOUR, P ;
BRANNON, J ;
ECKBERG, K ;
LLOYD, S ;
PURL, S ;
BLENDOWSKI, C ;
GOODMAN, M ;
BARNICLE, M ;
STEWART, I ;
MCHALE, M ;
BONOMI, P ;
KAPLAN, E ;
TAYLOR, S ;
THOMAS, CR ;
HARRIS, J .
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (03) :570-579
[9]  
Chren M M, 1999, J Cutan Med Surg, V3, P312
[10]   Improved discriminative and evaluative capability of a refined version of Skindex, a quality-of-life instrument for patients with skin diseases [J].
Chren, MM ;
Lasek, RJ ;
Flocke, SA ;
Zyzanski, SJ .
ARCHIVES OF DERMATOLOGY, 1997, 133 (11) :1433-1440